Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Barton A. Kamen"'
Autor:
Eati Basal, Guiti Z Eghbali-Fatourechi, Kimberly R Kalli, Lynn C Hartmann, Karin M Goodman, Ellen L Goode, Barton A Kamen, Philip S Low, Keith L Knutson
Publikováno v:
PLoS ONE, Vol 4, Iss 7, p e6292 (2009)
BACKGROUND:Despite low incidence, ovarian cancer is the fifth leading cause of cancer deaths and it has the highest mortality rate of all gynecologic malignancies among US women. The mortality rate would be reduced with an early detection marker. The
Externí odkaz:
https://doaj.org/article/482f84811a6445648d675706197da24d
Autor:
Ruth Croxford, S. E. Kim, Peter D. Cole, Robert C. Cho, Anna Ly, L. Ishiguro, Kyoung-Jin Sohn, Young-In Kim, Barton A. Kamen
Publikováno v:
British Journal of Cancer
Background: γ-Glutamyl hydrolase (GGH) regulates intracellular folate and antifolates for optimal nucleotide biosynthesis and antifolate-induced cytotoxicity, respectively. The modulation of GGH may therefore affect chemosensitivity of cancer cells,
Autor:
Angela K. Smith, Barton A. Kamen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 70:113-120
Folate is a cofactor in the synthesis of purines and pyrimidines; folate analogs are potent cytotoxic drugs. Folate receptor alpha (FRα), a protein-mediating cellular accumulation of folate (and anti-folates), has limited expression in normal tissue
Autor:
Laurent Brard, Shannon R. Lenox, Peter M. Bingham, Taka Ashikaga, Ajay P. Singh, Alan Homans, Giselle Saulnier Sholler, Barton A. Kamen, Barry W. Heath, Marni A Slavik, Genevieve Bergendahl, Timothy Higgins, William S. Ferguson
Publikováno v:
Journal of Pediatric Hematology/Oncology. 33:25-30
The primary aim of this phase 1 study was to determine the maximum tolerated dose (MTD) and evaluate the safety of nifurtimox alone and in combination with cyclophosphamide and topotecan in multiple relapsed/refractory neuroblastoma pediatric patient
Autor:
Richard H. Finnell, Joanne R. Lupton, Nysia I. George, Laurie A. Davidson, Barton A. Kamen, Evelyn S. Callaway, Robert S. Chapkin, Naisyin Wang
Publikováno v:
The Journal of Nutritional Biochemistry. 20:649-655
Inflammatory bowel disease (IBD) patients are at high risk for developing folate deficiency and colon cancer. Since it is difficult to study the subtle global and gene-specific epigenetic mechanisms involved in folate-mediated tumor initiation and pr
Autor:
Peter D. Cole, Barton A. Kamen, Angela K. Smith, Sudipta Roychowdhury, Veena Vijayanathan, Katherine A. Beckwith
Publikováno v:
Pediatric Neurology. 40:34-41
The neurotoxic effects of therapy for childhood acute lymphoblastic leukemia can result in leukoencephalopathy or measurable deficits in cognitive function. However, there are no validated biomarkers that allow the identification of those patients at
Publikováno v:
Clinical Genetics. 45:212-216
A 13-year-old male presented with new onset seizures, sagittal sinus thrombosis with cerebral hemorrhage, and extensive venous thrombosis of the lower limbs. Laboratory investigation demonstrated combined deficiency of protein C, protein S, and antit
Autor:
Peter D. Cole, I. David Goldman, Andong Qiu, John Glod, Barton A. Kamen, Stuti Ahlawat, Angela K. Smith, Benedette Makori, Rajeth Koneru, Jan B. Wollack, Sonia C. Picinich
Publikováno v:
Journal of Neurochemistry. 104:1494-1503
Reduced derivatives of folic acid (folates) play a critical role in the development, function and repair of the CNS. However, the molecular systems regulating folate uptake and homeostasis in the central nervous system remain incompletely defined. Ch
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:883-889
The DNA repair protein, O (6)-alkylguanine-DNA alkyltransferase (AGT), is a primary source of tumor resistance to agents such as temozolomide and chloroethylnitrosoureas that form DNA lesions at the O (6)-position of guanines. To increase the efficac
Autor:
Barton A. Kamen, Peter D. Cole
Publikováno v:
Mental Retardation and Developmental Disabilities Research Reviews. 12:174-183
Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the